8 unknown, 3 completed, 2 recruiting, 1 active not recruiting. 17 Phase 1, 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 17 | Unknown 8, Completed 3, Recruiting 2, Active not recruiting 1, Not yet recruiting 1, Terminated 1, Withdrawn 1 |
| Phase 2 | 6 | Unknown 4, Not yet recruiting 1, Terminated 1 |
Follow JS001: new trials by email Literature Review of JS001 trials Research Report on JS001
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| TMV Vaccine Alone or With Toripalimab-tpzi for Recurrent Head and Neck Squamous Cell Carcinoma TMV Vaccine, Toripalimab-tpzi - Squamous Cell Carcinoma of Head and Neck, Squamous Cell Carcinoma of Head and Neck (SCCHN) | Phase 1 | Recruiting | Metaclipse Therapeutics Corporation | 30 | 2026-10-01 | 2026-10-27 |
| Propranolol Hydrochloride Combined With Toripalimab and Platinum-based Chemotherapy in Resectable Non-Small Cell Lung Cancer Propranolol Hydrochloride, Toripalimab, Chemotherapy - Resectable Non-Small-Cell Lung Cancer | Phase 1 | Recruiting | Second Xiangya Hospital of Central South University | 9 | 2026-06-01 | 2026-10-21 |
| Newly Emerging Immunotherapy for Pancreatic Cancer Treatment JS001, JS004, JS007 - Pancreatic Cancer | Phase 1 / Phase 2 | Not yet recruiting | Fudan University | 117 | 2024-04-30 | 2024-04-17 |
| A Study of RC118 Plus Toripalimab / RC148 in Patients with Locally Advanced Unresectable or Metastatic Solid Tumors RC118, Toripalimab, RC148 - Advanced Solid Tumor | Phase 1 / Phase 2 | Unknown | RemeGen Co., Ltd. | 48 | 2023-08-03 | 2025-01-29 |
| KD6001 in Combination With Anti-PD-1 Antibody in Patients With Advanced Melanoma KD6001, Toripalimab - Melanoma | Phase 1 / Phase 2 | Unknown | Shanghai Kanda Biotechnology Co., Ltd. | 84 | 2023-03-22 | 2023-04-27 |
| Neo-T in Treating Patients With Advanced Solid Tumors(GI-NeoT-03) Neo-T, Toripalimab, Tislelizumab - Solid Tumor | Phase 1 | Unknown | BGI, China | 6 | 2023-01-10 | 2023-07-10 |
| A Clinical Study of TAB006 in Patients With Previously Treated, Advanced Malignancies TAB006, Toripalimab - Previously Treated, Advanced, Malignancies | Phase 1 | Withdrawn | Shanghai Junshi Bioscience Co., Ltd. | 2022-03-15 | 2022-05-31 | |
| A Study of ES102 (OX40 Agonist) in Combination With JS001 in Patients With Advanced Solid Tumors ES102, JS001 - Solid Tumor, Neoplasms | Phase 1 | Completed | Elpiscience Biopharma, Ltd. | 30 | 2021-10-15 | 2025-06-23 |
| Toripalimab Combined With Anlotinib and SBRT in Patients With Untreated Brain Metastases of Driven Gene-negative NSCLC Toripalimab, Anlotinib, SBRT 7Gy✖️5 QD - NSCLC | Phase 1 | Completed | Hubei Cancer Hospital | 13 | 2021-10-01 | 2025-02-07 |
| Donafenib and Toripalimab Combined With TACE in Patients With Unresectable Hepatocellular Carcinoma Donafenib Tosilate Tablets, Toripalimab Injection - Unresectable Hepatocellular Carcinoma | Phase 1 | Unknown | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 18 | 2021-01-08 | 2024-03-06 |
| Toripalimab Combined With Donafenib in the Treatment of Advanced Hepatocellular Carcinoma Donafenib Tosilate Tablets, Toripalimab Injection - Advanced Hepatocellular Carcinoma | Phase 1 / Phase 2 | Unknown | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 46 | 2020-10-15 | 2022-11-29 |
| Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy Atezolizumab, Avelumab, Cemiplimab - Advanced Malignant Skin Neoplasm, Metastatic Malignant Skin Neoplasm | Phase 1 | Active not recruiting | University of Southern California | 10 | 2020-08-12 | 2026-09-21 |
| Dose-escalation Study of APG-1387 and Toripalimab in Solid Tumors APG-1387 for Injection, Toripalimab - Advanced Solid Tumor | Phase 1 / Phase 2 | Terminated | Ascentage Pharma Group Inc. | 40 | 2020-04-10 | 2026-01-08 |
| Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies TAB004, Toripalimab - Advanced Unresectable Solid Tumor, Metastatic Solid Tumor | Phase 1 | Unknown | TopAlliance Biosciences | 499 | 2019-10-30 | 2024-02-05 |
| JS001 Combined With Regorafenib in Patients With Advanced Colorectal Cancer JS001, regorafenib tablet - Colorectal Cancer | Phase 1 / Phase 2 | Unknown | Sun Yat-sen University | 44 | 2019-03-12 | 2020-05-12 |
| Study of JS001 in Patients With Advanced Neuroendocrine Tumors humanized anti-PD-1 monoclonal antibody - Neuroendocrine Tumors | Phase 1 | Completed | Peking University | 40 | 2017-04-06 | 2019-06-21 |
| Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of an Anti-PD-1 mAb for Patients With Advanced Solid Tumors JS001 - Lymphoma, Lung Cancer | Phase 1 | Unknown | Shanghai Junshi Bioscience Co., Ltd. | 33 | 2016-08-01 | 2019-10-22 |
Carcinoma, Non-Small-Cell Lung (3) · Melanoma (3) · Lymphoma (2) · Neoplasms (2) · Brain Neoplasms (1) · Colorectal Neoplasms (1) · Hypopharyngeal Neoplasms (1) · Laryngeal Neoplasms (1) · Lung Neoplasms (1) · Mouth Neoplasms (1) · Neoplasm Metastasis (1) · Neoplasm Recurrence, Local (1) · Neuroendocrine Tumors (1) · Oropharyngeal Neoplasms (1) · Pancreatic Neoplasms (1)
Shanghai Junshi Bioscience Co., Ltd. (2) · Suzhou Zelgen Biopharmaceuticals Co.,Ltd (2) · Ascentage Pharma Group Inc. (1) · BGI, China (1) · Elpiscience Biopharma, Ltd. (1) · Fudan University (1) · Hubei Cancer Hospital (1) · Metaclipse Therapeutics Corporation (1) · Peking University (1) · RemeGen Co., Ltd. (1) · Second Xiangya Hospital of Central South University (1) · Shanghai Kanda Biotechnology Co., Ltd. (1) · Sun Yat-sen University (1) · TopAlliance Biosciences (1) · University of Southern California (1)
China (13) · United States (3)
Sheng Yao, PhD (2) · Christopher Pack, PhD (1) · Gino K In, MD (1) · Jian Zhang, Doctor (1) · Kristen Jacobsen, PhD (1) · Lin Shen, MD, PhD (1) · Michael Coleman, PhD (1) · Periasamy Selvaraj, PhD (1) · Qing Xu, Doctor (1) · Rui-hua Xu, PhD (1) · Shanzhi Gu, MD (1) · Shukui Qin, PhD (1) · Tianshu Liu, ph.D (1) · Yifan Zhai, M.D., Ph.D. (1) · Yong Chen, Doctor (1)
PMID 25213161, PMID 25981818, PMID 26755520, PMID 30522017, PMID 30642373, PMID 32086343, PMID 32224416
P30CA014089 (1)